# To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

> **NCT07116473** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Eidos Therapeutics, a BridgeBio company** · enrollment: 250 (estimated)

## Conditions studied

- Amyloidosis in Transthyretin (TTR)
- Amyloidosis, Familial
- Amyloid Cardiomyopathy
- Amyloid Cardiomyopathy, Transthyretin-Related
- Amyloidogenic Transthyretin (ATTR) Amyloidosis
- Heart Disease
- Cardiomyopathies
- Amyloidosis, Hereditary, Transthyretin-Related
- Polyneuropathies
- Amyloidosis

## Interventions

- **DRUG:** Acoramidis (AG10)

## Key facts

- **NCT ID:** NCT07116473
- **Lead sponsor:** Eidos Therapeutics, a BridgeBio company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11
- **Primary completion:** 2037-11
- **Final completion:** 2037-12
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07116473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07116473, "To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)". Retrieved via AI Analytics 2026-09-11 from https://api.ai-analytics.org/clinical/NCT07116473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*